Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PIXY321 data

IMNX reported on a Phase I/II trial in pediatric patients receiving ICE (ifosfamide/carboplatin/etoposide) chemotherapy.

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE